Replies to post #217355 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

I said I agree to NO FULL BUYOUT. No way! A sale of one drug? Absolutely if the price is right. Let’s discuss Prurisol. The trial design for phase 2b is an apples to apples view against the blockbuster oral drug Otezla. Otezla set the bar at 30-33% PASI 75.

That’s simple to compare.

I know Georgjii says Prurisol may help other indications as does the company, but as of now it’s the dark horse drug candidate.

If I ran the company and knew B and Ks possible value and believed P to be a drug for just P psoriasis I would for sure sell if results were great.

I believe the Oral psoriasis market is extremely valuable today and anything over 30% PASI 75 would garner a multi billion sale of said drug.

Remember; it has the 505 2b designation that will allow a cheaper phase 3 and also offer a possibility to a 3-5 year exclusivity extension (huge) and P is cheap to manufacturer and also extremely safe and not to mention is fully owned by IPIX - no profit sharing. All of that makes the drug extremely easy to sell outright for a premium imo.

So let’s say they hit 50% PASI 75 - ummm. Boom! Many Billion buyout easy. If it’s Georgjii style results 10 Billion buyout easy of drug.


But to sell the entire company right now. IMO. Hahaha. No way.